Therapies with HER2-targeting monoclonal antibodies (mAbs), such as trastuzumab and pertuzumab, have shown promising clinical benefits in treating HER2- overexpressing cancers for decades [7,8,9]. This evidence concerns the gene ERBB2 and cancer.